The roundup is formatted with the title of the story, followed by the news source in parentheses and a brief summary. If you find a particularly interesting article, please send it to email@example.com for inclusion in next week’s roundup.
Should Genetically Modified Babies Be Legal? (Newsmax) With CRISPR-Cas9 technology, it is now within the reach of scientists to modify the genes of embryos, but should we?
Scientific rigor and reproducibility
With recent attention on the reported irreproducibility of scientific studies from cancer to psychology research, scientists are fixed on finding the solution.
Reproducing results: how big is the problem? (The Times Higher Education)
The Great Big Clean-Up (The Scientist)
U.S. Department of Health and Human Services released a Federal Register notice describing intended changes to the Common Rule. These changes will require federal departments and agencies to simplify and broaden consent authorization paperwork for patients in human trials and streamline multi-university ethical review.
U.S. to finalize new human subject protections (Science Insider)
Federal Plan to Modernize Medical Trials’ Rules Would Be Boon to Universities (The Chronicle of Higher Education)
Giant study poses DNA data-sharing dilemma (Nature) The Precision Medicine Initiative working group is set to release a project plan next month and anticipation is building to learn how much genetic information will be shared with participants.
Google Life Sciences Makes Diabetes Its First Big Target (WIRED) Google, now Alphabet, will partner with pharmaceutical company Sanofi to take on diabetes as their first biomedical research mission.
As federal research funding has stagnated over the past decade, states such a Georgia and New York, concerned with recruiting top scientific talent to their universities, have taken matters into their own hands.
The Battle for Biomedical Supremacy (The New York Times)
‘Eminent’ researchers recruited (Athens Banner-Herald)
Fetal tissue research offers the potential for tremendous biomedical advances despite recent negative attention.
Fetal Tissue Fallout (NEJM)